These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 9601894)

  • 1. [Plasminogen activator inhibitor (PAI-1) and diabetes mellitus. I. Regulation of PAI-1 levels].
    Galajda P; Sutarík L; Vladár L; Stasko J; Kubisz P; Mokán M
    Vnitr Lek; 1997 Dec; 43(12):804-8. PubMed ID: 9601894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A multicomparmental and multifactorial model of production of plasminogen activator inhibitor (PAI-1). I. Experimental studies].
    Galajda P; Kubisz P; Mokán M
    Vnitr Lek; 1998 Dec; 44(12):718-21. PubMed ID: 10422516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasminogen activator inhibitor (PAI-1) and diabetes mellitus. II. PAI-1 in insulin resistant conditions].
    Galajda P; Sutarík L; Vladár L; Stasko J; Kubisz P; Mokán M
    Vnitr Lek; 1998 Feb; 44(2):111-4. PubMed ID: 9820087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
    Takeshita Y; Takamura T; Hamaguchi E; Shimizu A; Ota T; Sakurai M; Kaneko S
    Metabolism; 2006 Nov; 55(11):1464-72. PubMed ID: 17046548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo.
    Nordt TK; Sawa H; Fujii S; Bode C; Sobel BE
    J Mol Cell Cardiol; 1998 Aug; 30(8):1535-43. PubMed ID: 9737940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo stimulation of vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element.
    Dichtl W; Ares MP; Stollenwerk M; Giachelli CM; Scatena M; Hamsten A; Eriksson P; Nilsson J
    Thromb Haemost; 2000 Oct; 84(4):706-11. PubMed ID: 11057874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A multicompartmental and multifactorial model of production of plasminogen activator inhibitor (PAI-1). II. Clinical study in patients with insulin resistance].
    Galajda P; Kubisz P; Mokán M
    Vnitr Lek; 1999 Jan; 45(1):62-6. PubMed ID: 10422529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus].
    Olexa P; Olexová M
    Vnitr Lek; 2003 Mar; 49(3):222-6. PubMed ID: 12728597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
    Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
    Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
    Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
    Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
    De Taeye B; Smith LH; Vaughan DE
    Curr Opin Pharmacol; 2005 Apr; 5(2):149-54. PubMed ID: 15780823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
    Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
    Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of plasminogen activator inhibitor-1 and tissue plasminogen activator in the kidney of KKAy mice with type 2 diabetes].
    Chen LM; Li XW; Huang LW; Li Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):344-8. PubMed ID: 16038272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients.
    Bonfigli AR; Pieri C; Manfrini S; Testa I; Sirolla C; Ricciotti R; Marra M; Compagnucci P; Testa R
    Diabetes Nutr Metab; 2001 Apr; 14(2):71-7. PubMed ID: 11383676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms].
    Banfi C; Mussoni L; Tremoli E
    Minerva Endocrinol; 2002 Sep; 27(3):181-91. PubMed ID: 12091793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells.
    Hamaguchi E; Takamura T; Shimizu A; Nagai Y
    J Pharmacol Exp Ther; 2003 Dec; 307(3):987-94. PubMed ID: 14534369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.